St. Jude finds factors that accelerate resistance to targeted therapy in lymphoblastic leukemia
Results of a study by investigators at St. Jude Children's Research Hospital provide strong evidence for why the targeted therapy drug imatinib (Gleevec™), which has revolutionized the treatment of chronic myelogenous leukemia (CML), is often unable to prevent relapse of a particularly aggressive form of acute lymphoblastic leukemia (ALL).